Pathophysiological mechanisms of COVID-19-related endothelial dysfunction and potential therapies

NewsGuard 100/100 Score

In a recent review published in Life, researchers discussed the pathophysiological mechanisms of endothelial dysfunction associated with severe coronavirus disease 2019 (COVID-19). They commented on the potential therapeutic strategies to treat endothelial damage and coagulopathy related to COVID-19.

Study: Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options. Image Credit: MIA Studio/Shutterstock
Study: Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options. Image Credit: MIA Studio/Shutterstock


Emerging research shows that while severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection primarily targets the pulmonary and respiratory systems, long-lasting health concerns associated with micro-thromboembolism, myocardial injury, myocarditis, and renal failure have been observed in COVID-19 patients. A growing body of evidence indicates that endothelial damage due to the viral infection and the inflammatory response during COVID-19 could contribute to the severity of the disease.

Endothelial cells regulate inflammation, coagulation, dilation of blood vessels, and oxidative stress. Studies have shown that vascular endothelial damage and dysfunction contribute significantly to severe pulmonary outcomes during COVID-19. Furthermore, many extrapulmonary COVID-19 symptoms have also been linked to endothelial dysfunction. Exploring the pathophysiology of endothelial damage and investigating potential treatment methods could help limit severe COVID-19 outcomes.

Endothelial dysfunction

The review reported the possible mechanisms that explain the SARS-CoV-2 tropism towards endothelial cells. Viral entry into the host cell begins with the binding of the SARS-CoV-2 spike protein to the angiotensin-converting enzyme-2 (ACE-2) receptor and downstream activation of the spike protein subunits. The ACE-2 enzyme modulates the renin-angiotensin-aldosterone system (RAAS) signaling pathway, which controls local and systemic blood flow and pressure.

Interactions of the spike protein with the nuclear factor κB pathway and integrin α5β1 are thought to cause endothelial damage. SARS-CoV-2 is also thought to alter the endothelial glycocalyx integrity and apoptosis of endothelial cells.

The authors also discussed the inflammation and hypercoagulability resulting from endothelial damage. Endothelial cells produce endogenous molecules such as prostaglandin and nitric oxide that are involved in controlling platelet aggregation and maintaining vascular homeostasis. Endothelial damage induces hypercoagulation and contractions of the vasculature, resulting in an increased risk of thromboembolic events. Hypercoagulation also reduces blood flow to other regions, such as the kidneys and myocardium, causing disseminated intravascular coagulation.

Severe COVID-19 is associated with extremely elevated levels of interleukins (IL) such as IL-1β, IL-10, IL-6, and IL-7, also known as “cytokine storm,” which increases tumor necrosis factor secretion and interferon-γ induced apoptosis. The elevated cytokines cause endothelial damage, which further increases the secretion of inflammatory molecules, causing a cyclic reaction.

Endothelial dysfunction and SARS-CoV-2 variants

The review investigated studies that compared the transmission, virulence, and immune evasion of SARS-CoV-2 variants of concern. The results indicated that while the Omicron variant had mutations in the spike protein and receptor binding domain that resulted in immune evasion and high transmission, it caused lower severity and did not affect the endothelial cells as much as the Delta variant. Studies found fewer incidences of pulmonary embolism associated with the Omicron variant.

Manifestations and mechanisms

The pulmonary manifestations range from mild to severe and vary according to comorbidities, age, sex, viral load, genetics, and ethnicity. The symptoms include upper respiratory tract infections to hypoxia, acute respiratory distress syndrome, and pulmonary edema.

Extrapulmonary manifestations can be seen in multiple organ systems, including the cardiac, renal, nervous, and gastrointestinal systems. Complications include arrhythmias, myocarditis, proteinuria, kidney failure, seizures, encephalopathy, cerebrovascular disease, intestinal inflammations, deep vein thrombosis, and many more.

Emerging research on “long COVID” have revealed that endothelial damage is one of the contributing factors to the chronic systemic concerns such as thrombosis, fatigue, cardiac complications such as myocardial hypertrophy, and neurodegenerative symptoms experienced by COVID-19 patients in the months following their recovery.

Therapeutic avenues

Data from clinical trials suggest various treatment strategies to target coagulopathy and endothelial damage caused by COVID-19. Low molecular weight heparin exhibits antiviral and anti-inflammatory activity in addition to its antithrombotic effects. Corticosteroids are generally used to treat the respiratory symptoms of SARS-CoV-2 infections. Additionally, corticosteroids exhibit anti-inflammatory activity and reduce pro-coagulation factors like fibrinogen and von Willebrand factor.

Although controversial because of their role in increasing ACE-2 receptor expression and potentially facilitating viral entry, RAAS inhibitors are also thought to reduce endothelial damage. The authors also presented a comprehensive summary of the studies that discuss the use of statins, antiviral agents, and monoclonal antibodies in addressing endothelial dysfunction and hypercoagulation.


To summarize, the review discussed the possible pathophysiological mechanisms of endothelial dysfunction that results from severe COVID-19 and causes immediate and long-term multi-organ damage. Endothelial dysfunction mostly manifests as hypercoagulation and inflammation, and the extent of endothelial damage varies based on the SARS-CoV-2 variant of concern.

The authors presented data from various clinical trials on the use of heparins, RAAS inhibitors, corticosteroids, monoclonal antibodies, and many more therapeutic options which could potentially be used to reduce the endothelial damage caused by severe SARS-CoV-2 infections.

Journal reference:
Dr. Chinta Sidharthan

Written by

Dr. Chinta Sidharthan

Chinta Sidharthan is a writer based in Bangalore, India. Her academic background is in evolutionary biology and genetics, and she has extensive experience in scientific research, teaching, science writing, and herpetology. Chinta holds a Ph.D. in evolutionary biology from the Indian Institute of Science and is passionate about science education, writing, animals, wildlife, and conservation. For her doctoral research, she explored the origins and diversification of blindsnakes in India, as a part of which she did extensive fieldwork in the jungles of southern India. She has received the Canadian Governor General’s bronze medal and Bangalore University gold medal for academic excellence and published her research in high-impact journals.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sidharthan, Chinta. (2022, October 19). Pathophysiological mechanisms of COVID-19-related endothelial dysfunction and potential therapies. News-Medical. Retrieved on May 20, 2024 from

  • MLA

    Sidharthan, Chinta. "Pathophysiological mechanisms of COVID-19-related endothelial dysfunction and potential therapies". News-Medical. 20 May 2024. <>.

  • Chicago

    Sidharthan, Chinta. "Pathophysiological mechanisms of COVID-19-related endothelial dysfunction and potential therapies". News-Medical. (accessed May 20, 2024).

  • Harvard

    Sidharthan, Chinta. 2022. Pathophysiological mechanisms of COVID-19-related endothelial dysfunction and potential therapies. News-Medical, viewed 20 May 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study suggests lingering coronavirus in tissues may contribute to long COVID symptoms